AstraZeneca and Oxford University released preliminary results of Round 3 of clinical trials of the vaccine against coronavirus in the USA. According to the press office of AstraZeneca company, the vaccine completely prevents severe course of the disease.
Clinical trials in Peru and Chile showed that the drug also offers considerable protection against the symptoms of this sickness.
"The AstraZeneca US Phase III trial of AZD1222 demonstrated statistically significant vaccine efficacy of 79% at preventing symptomatic COVID-19 and 100% efficacy at preventing severe disease and hospitalisation", reads the statement.
According to AstraZeneca, "the analysis was based on 32,449 participants accruing 141 symptomatic cases of COVID-19. The trial had a 2:1 randomisation of vaccine to placebo. Vaccine efficacy was consistent across ethnicity and age. Notably, in participants aged 65 years and over, vaccine efficacy was 80%".
The company claimed that all participants tolerated the vaccine well, and the independent committee did not observe any problems with the vaccine's safety. It also "found no increased risk of thrombosis or events characterised by thrombosis among the 21,583 participants receiving at least one dose of the vaccine", AstraZeneca claimed.